Practice patterns in NAFLD and NASH: Real life differs from published guidelines

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 1, 2016, Pages 4-12

  Rinella, Mary E ^a   Lominadze, Zurabi ^a   Loomba, Rohit ^b   Charlton, Michael ^c   Neuschwander Tetri, Brent A ^d   Caldwell, Stephen H ^e   Kowdley, Kris ^f   Harrison, Stephen A ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

Author keywords

diagnosis; liver biopsy; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; pioglitazone; practice guidelines; practice patterns; treatment

Indexed keywords

ALPHA TOCOPHEROL; METFORMIN; PIOGLITAZONE;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BARIATRIC SURGERY; CLINICAL PRACTICE; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; GASTROENTEROLOGIST; HEPATOLOGIST; HUMAN; LIVER BIOPSY; MEDICAL SPECIALIST; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; PUBLISHING; UNITED STATES;

EID: 84951861083     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15611581     Document Type: Article

References (34)

1. Adams T. Gress R. Smith S. Halverson R. Simper S. Rosamond W. et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357: 753–761.
2. Berry D. Wathen J. Newell M. (2009) Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality. Clin Trials 6: 28–41.
3. Breunig I. Shaya F. McPherson M. Snitker S. (2014) Development of heart failure in medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin. J Manag Care Pharm 20: 895–903.
4. Caiazzo R. Lassailly G. Leteurtre E. Baud G. Verkindt H. Raverdy V. et al. (2014) Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 260: 893–898; discussion 898–899.
5. Chalasani N. Younossi Z. Lavine J. Diehl A. Brunt E. Cusi K. et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005–2023.
6. Chen H. Shieh J. Chang C. Chen T. Lin J. Wu M. et al. (2013) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62: 606–615.
7. Curtis A. Bullen M. Piccenna L. McNeil J. (2014) Vitamin e supplementation and mortality in healthy people: a meta-analysis of randomised controlled trials. Cardiovasc Drugs Ther 28: 563–573.
8. Donadon V. Balbi M. Mas M. Casarin P. Zanette G. (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30: 750–758.
9. Dykema J. Jones N. Piche T. Stevenson J. (2013) Surveying clinicians by web: current issues in design and administration. Eval Health Prof 36: 352–381.
10. Fracanzani A. Valenti L. Bugianesi E. Andreoletti M. Colli A. Vanni E. et al. (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48: 792–798.
11. Gerss J. Kopcke W. (2009) The questionable association of vitamin E supplementation and mortality – inconsistent results of different meta-analytic approaches. Cell Mol Biol 55(Suppl.): OL1111–OL1120.
12. Haukeland J. Konopski Z. Eggesbo H. von Volkmann H. Raschpichler G. Bjoro K. et al. (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44: 853–860.
13. Klein E. Thompson I. Jr. Tangen C. Crowley J. Lucia M. Goodman P. et al. (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549–1556.
14. Lai S. Chen P. Liao K. Muo C. Lin C. Sung F. (2012) Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 107: 46–52.
15. Lassailly G. Caiazzo R. Buob D. Pigeyre M. Verkindt H. Labreuche J. et al. (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149: 379–388.
16. Levin D. Bell S. Sund R. Hartikainen S. Tuomilehto J. Pukkala E. et al. (2014) Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58: 493–504.
17. Lian J. Liang Y. (2014) Diabetes management in the real world and the impact of adherence to guideline recommendations. Curr Med Res Opin 30: 2233–2240.
18. Lonn E. Bosch J. Yusuf S. Sheridan P. Pogue J. Arnold J. et al. (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293: 1338–1347.
19. Marchioli R. Levantesi G. Macchia A. Marfisi R. Nicolosi G. Tavazzi L. et al. (2006) Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. J Cardiovasc Med 7: 347–350.
20. Mathurin P. Hollebecque A. Arnalsteen L. Buob D. Leteurtre E. Caiazzo R. et al. (2009) Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137: 532–540.
21. Miller E. 3rd Pastor-Barriuso R. Dalal D. Riemersma R. Appel L. Guallar E. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142: 37–46.
22. Mofrad P. Contos M. Haque M. Sargeant C. Fisher R. Luketic V. et al. (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37: 1286–1292.
23. Mummadi R. Kasturi K. Chennareddygari S. Sood G. (2008) Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6: 1396–1402.
24. Omer Z. Cetinkalp S. Akyildiz M. Yilmaz F. Batur Y. Yilmaz C. et al. (2010) Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 22: 18–23.
25. Ratziu V. Bellentani S. Cortez-Pinto H. Day C. Marchesini G. (2010) A position statement on NAFLD / NASH based on the EASL 2009 special conference. J Hepatol 53: 372–384.
26. Ratziu V. Cadranel J. Serfaty L. Denis J. Renou C. Delassalle P. et al. (2012) A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol 57: 376–383.
27. Sanyal A. Chalasani N. Kowdley K. McCullough A. Diehl A. Bass N. et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675–1685.
28. Schurks M. Glynn R. Rist P. Tzourio C. Kurth T. (2010) Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ 341: c5702.
29. Shields W. Thompson K. Grice G. Harrison S. Coyle W. (2009) The effect of metformin and standard therapy versus standard therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2: 157–163.
30. Sjostrom L. Narbro K. Sjostrom C. Karason K. Larsson B. Wedel H. et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741–752.
31. Sloan K. Sales A. Willems J. Every N. Martin G. Sun H. et al. (2001) Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results < or=100 mg / dl among patients who had coronary events (Northwest VA Network Study). Am J Cardiol 88: 1143–1146.
32. Vernon G. Baranova A. Younossi Z. (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274–285.
33. Williams C. Stengel J. Asike M. Torres D. Shaw J. Contreras M. et al. (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124–131.
34. Zhang Z. Zheng Z. Shi R. Su Q. Jiang Q. Kip K. (2012) Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97: 2347–2353.